key: cord-0932254-ifzubdqp authors: Shurrab, Farah M.; Younes, Nadin; Al-Sadeq, Duaa W.; Liu, Na; Qotba, Hamda; Abu-Raddad, Laith J.; Nasrallah, Gheyath K. title: Performance evaluation of novel fluorescent-based lateral immune flow assay (LIFA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals date: 2022-02-26 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2022.02.052 sha: ea4a770e40edcb8a0848823c50afe2470efa5a18 doc_id: 932254 cord_uid: ifzubdqp Background : The vast majority of the commercially available LFIA is used to detect SARS-CoV-2 antibodies qualitatively. Recently, a novel fluorescence-based LIFA test was developed for quantitative measurement of the total binding antibody units (BAU/mL) against the receptor-binding domain of the SARS-CoV-2 spike protein (S-RBD). Aim : To evaluate the performance of the fluorescence LIFA FinecareTM 2019-nCoV S-RBD test along with its reader (Model No.: FS-113). Methods : Plasma from 150 RT-PCR confirmed-positive individuals and 100 pre-pandemic samples were tested by FinCareTm to access sensitivity and specificity. For qualitative and quantitative validation of the FinCarTm measurements, the BAU/mL results of FinCareTm were compared with results of two reference assays: the surrogate virus-neutralizing test (sVNT, GenScript, USA), and the VIDAS®3 automated assay (BioMérieux, France). Results : FinecareTM showed 92% sensitivity and 100% specificity compared to PCR. Cohen's Kappa statistic denoted moderate and excellent agreement with sVNT and VIDAS®3, ranging from 0.557 (95% CI: 0.32-0.78) to 0.731 (95% CI: 0.51-0.95), respectively. A strong correlation was observed between FinecareTM/sVNT (r=0.7, p<0.0001) and FinecareTM/VIDAS®3 (r=0.8, p<0.0001). Conclusion : FinecareTM is a reliable assay and can be used as a surrogate to assess binding and neutralizing antibody response post-infection or vaccination, particularly in none or small laboratory settings.  Finecare TM test can be used to predict the amount of neutralizing antibodies. Finecare TM showed 92% sensitivity and 100% specificity compared to PCR. Cohen's Kappa statistic denoted moderate and excellent agreement with sVNT and VIDAS®3, ranging from 0.557 (95% CI: 0.32-0.78) to 0.731 (95% CI: 0.51-0.95), respectively. A strong correlation was observed between Finecare TM /sVNT (r=0.7, p<0.0001) and Finecare TM /VIDAS®3 (r=0. 8, p<0 .0001). Conclusion: Finecare TM is a reliable assay and can be used as a surrogate to assess binding and neutralizing antibody response post-infection or vaccination, particularly in none or small laboratory settings. Keywords: SARS-CoV-2; COVID-19; Serology; Lateral Flow Assay; Fluorescence immunoassay. Soon after the emergence of the severe acute respiratory syndrome 2 (SARS-CoV-2) in December 2019 and its declaration as a pandemic by the World Health Organization (WHO), the need for accurate, sensitive, and rapid detection of SARS-CoV-2 for the control and prevention of the disease was was urgent (Theel et al., 2020) . Several commercial COVID-19 test kits were developed in response to this urgent need for the detection of either nucleic acid or antibodies (Van Walle et al., 2021). Although RT-PCR is used as a gold standard test, it requires specialized conditions, expensive equipment, and qualified personnel for sampling and testing. These limitations pose a challenge in a pandemic setting which requires rapid and reliable tests that can be used to screen populations (Dortet et al., 2021) . Thus, serological testing, particularly pointof-care approaches, such as the lateral flow immunoassay (LFIA), provides a rapid, portable and coast effective method that is complementary to the RT-PCR. In addition, serological tests have important applications in public health; they can be used in epidemiological survey studies, detect past infections, and determine herd immunity in the community. Furthermore, serological tests have a vital role in convalescent plasma treatment and determining vaccines effectiveness (Nadoushan et al., 2020) . Conventional LFIA used in clinical settings for diagnosing SARS-CoV-2 infection are done manually within 15 minutes, and the results are interrupted qualitatively by the naked eye. As a result, errors due to manual operation and inadequate visual sensitivity interpretation can occur. Recently, Wondfo Biotech developed Fluorescence-based LIFA to detect total anti-S- Test is a fluorescence immunoassay that is done semiautomatically along with a small portable device . The combination of fluorescence and LIFA provides higher sensitivity, quantitative detection of antibodies and is easily affordable and accessible in small clinical laboratory, research settings or poit of care testing pos-infection or vaccination. To the best of our knowledge, there is only one paper in the literature evaluating the rapid fluorescence-based LFIA immunoassays, which aimed to validate the performance of rapid SARS-CoV-2 IgM and IgG test kits based on fluorescence immunochromatography (Kang et al., 2021) . In this study, we aimed to evaluate the performance of a rapid semiautomated fluorescence-based LIFA. This assay is designated to provide qualitative and quantitative measurements of SARS-CoV-2 anti-S-RBD total antibodies. One of the most advantages of this assay over the commercially available LIFA is not only results are quantitative but also converted to BAU/mL (instead of arbitrary ARU/mL) as recently recommended by the WHO. We evaluated the performance of FineCare TM 2019-nCOV Antibody test and it's reader The sensitivity FineCare TM was determined using 150 sera from RT-PCR-confirmed individuals (7 ->21 days). Qiagen extraction kit was used to extract RNA from nasopharyngeal swab specimens. Then, the SuperscriptIII OneStep RT-PCR kit was used to test for SARS-CoV- Complete descriptions for these participants are summarized in Table S1 . The specificity was examined using 100 pre-pandemic plasma samples collected before 2019, which were used in previous studies (Nasrallah et The FDA-approved SARS-CoV-2 surrogate virus neutralization test The test was done according to the manufacturer's instructions. An inhibition value of ≥ 30% signal inhibition was considered positive, and < 30% signal inhibition was considered negative. The WHO international standardization factor for this assay was used to convert readings from % inhibition to International units per milliliter (IU/mL) by applying the recently published formula (Zhu et al., 2021). Using the RT-PCR as the reference test, sensitivity, specificity, overall percent agreement, and Cohen's Kappa coefficient were calculated to assess the Performance of Receiving operating characteristic (ROC) curve and Youden index were conducted to assess the assay threshold (cut-off indices) and identify optimized one, and measure the area under the curve (AUC). The relation between AUC and diagnostic accuracy is direct. The larger the AUC the more accurate a test can be considered in its overall performance. Statistically, an AUC of <0.5 suggests no discrimination, 0.7-0.8 is considered acceptable, 0.8-0.9 is considered excellent, and >0.9 is considered outstanding. To determine the optimal threshold for optimal sensitivity and specificity for FineCare TM , the Youden's index (J) was calculated using the formula: J= max The overall diagnostic performance of FineCare TM analyzer compared to RT-PCR is summarized in Table1. The of FineCare TM sensitivity and specificity were 92% (95% CI: 86.44% to 95.80%) and 100% (95% CI: 96.38%-100.00%), respectively. The overall percent agreement with RT-PCR was 96.4% (95% CI: 93.2%-98.1%). The Cohen's Kappa statistic with RT-PCR denoted an excellent agreement with κ coefficient of 0.881 (95% CI: 0.816-0.946). The tests' concordance assessment is summarized in Figure 1 . Both immunoassays showed strong correlation with FineCare TM . Pearson's correlation coefficients (r) ranged from 0.70 for FineCare TM /sVNT to 0.8 for FineCare TM / VIDAS®3. ROC curve analyses showed excellent Performance for FineCare TM with an AUC of 0.9627, and p<0.0001 (Figure 2 ). Based on the ROC curves and the calculated Youden's index, the optimized cut-off for detecting total antibodies against RBD was derived. The cut-off obtained was > 10.70, compared to the manufacturer's cut-off ≥ 20. Applying this new cut-off showed improved sensitivity, from 92% to 94.67%, while the specificity remained 100% (Table 1) . Previously, we reported that the sensitivity of the immunoassay was higher in symptomatic patients than in the asymptomatic patient group . Addiotionally, the sensitivity of the Fincare assay for estimating anti-SARBD or neutralizing antibodies could be overestimated, as the S-RBD antigen in this assay is designed to detect antibodies specific to the wild-type (Wuhan) but not the other SARS-CoV-2 variants. Some of these variants, such as Omicron, accumulates significant numbers of mutations in the S-RBD domain. These mutations might decrease the affinity of the binding and neutralizing antibodies to the S-RBD, which intern, affect the sensitivity of the assay. We evaluated the degree of correlation between FineCare TM with sVNT and VIDAS®3. A strong correlation was obtained between FineCare TM and both assays (Figure1); however, VIDAS®3 showed a slightly higher correlation. This is because both VIDAS®3 and FineCare TM detection methods are based on enzyme-linked fluorescent and target antibodies against the S-RBD domain. This is particularly important; the FineCare TM rapid antibody test could detect neutralizing antibodies and serve as a surrogate for the advanced automated immunoassays in clinical settings to measure the humoral immune response after vaccination or infection and research context. ROC curve analysis was also performed to determine the optimal cut-off indices for FineCare TM (Figure 2 ). The new cut-off value showed improved sensitivity without affecting the specificity. However, the cut-off values could be adjusted depending on the clinical setting or research context. For instance, in high-prevalence settings, higher thresholds may be desirable for screening purposes, whereas lower cut-off may be helpful for diagnosis purposes (Ismail et al., 2021) . Our study had some limitations; most of our RT-PCR samples were collected from asymptomatic individuals (Table S1 ), which might have underestimated the assay's sensitivity. In addition, the control group did not include samples for other coronaviruses or influenza that might cross-react with SARS-CoV-2, which could have led to an overestimated specificity. In conclusion, depending on characteristics of emerging variants, our data showed that FineCare TM 2019-RBD antibody test demonstrated excellent performance in terms of sensitivity, specificity, and overall agreement with RT-PCR as a reference test. In addition, correlation with the FDA-approved sVNT from Genscript and the automated analyzer VIDAS®3 from bioMérieux, FineCare TM immunoassay showed an outstanding performance in detecting total antibodies in serum samples against SARS-CoV-2. Thus, this assay could be reliable for the quantitative detection of antibodies in the vaccinated population and recovered patients. 2019-nCoV RBD Antibody Tes 2019-nCoV RBD Antibody Test; Available from: www.wondfo.com.cn Evaluation of antibody response in symptomatic and asymptomatic COVID-19 patients and diagnostic assessment of new IgM/IgG ELISA kits Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar. medRxiv Comparison of classification accuracy using Cohen's Weighted Kappa. Expert Systems with Applications Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Evaluating 10 commercially available SARS-CoV-2 rapid serological tests by use of the STARD (Standards for Reporting of Diagnostic Accuracy Studies) method Estimation of the Youden Index and its associated cutoff point Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays Development, performance evaluation, and clinical application of a Rapid SARS-CoV-2 IgM and IgG Test Kit based on automated fluorescence immunoassay Interrater reliability: the kappa statistic Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). Emerging microbes & infections Serology testing for SARS-CoV-2: Benefits and challenges Estimating seroprevalence of herpes simplex virus type 1 among different Middle East and North African male populations residing in Qatar Performance of four diagnostic assays for detecting herpes simplex virus type 2 antibodies in the Middle East and North Africa Performance Characteristics of the Vidas SARS-CoV-2 IgM and IgG Serological Assays Measuring influenza hemagglutinin (HA) stem-specific antibody-dependent cellular cytotoxicity (ADCC) in human sera using novel stabilized stem nanoparticle probes Statistics at square one: Bmj London Epidemiology of SARS-CoV2 in Qatar's primary care population aged 10 years and above A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike proteinprotein interaction The role of antibody testing for SARS-CoV-2: is there one? Defining an optimal cut-point value in ROC analysis: an alternative approach. Computational and mathematical methods in medicine Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19 Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies Diagnostic efficiency of three fully automated serology assays and their correlation with a novel surrogate virus neutralization test in symptomatic and asymptomatic SARS-COV-2 individuals Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019 WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. The Lancet Microbe ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:We would like to declare that all test kits used in this study were provided as in-kind support for GKN lab to test seroprevalence of anti-SARS-CoV-2 and antibody response among vaccinated and infected individuals in Qatar.